Answers are grounded in this paper and cite their sources.
Colorectal cancer (CRC) remains a major clinical challenge, and the c-Jun N-terminal kinase (JNK) signaling pathway represents a compelling yet pharmacologically complex target. Two tetracyclic ketoxime JNK inhibitors, 11H-indeno[1,2-b]quinoxalin-11-one oxime (IQ-1) and 6-(hydroxyimino)indolo[2,1-b]quinazolin-12(6H)-one (tryptanthrin-6-oxime, TRP-Ox), have previously demonstrated anti-inflammatory activity, but their direct antitumor potential against CRC has not been systematically investigated. In this study, we evaluated the in vitro and in vivo efficacy of both compounds against human SW620 colon adenocarcinoma models. Reverse pharmacophore screening of the compound’s isomers confirmed JNK1 and JNK3 as primary predicted targets alongside shared cancer-relevant effectors (including CDK2, Cyclin A2, VEGFR2, GSK3β, PTP1B, HSP90α, and MMP3), suggesting a polypharmacological mode of action. In vitro proliferation was monitored continuously via real-time impedance analysis (iCELLigence), while cell death was quantified after 24 h using annexin V/propidium iodide flow cytometry. Both compounds suppressed SW620 cell growth, driving cytotoxicity predominantly through early and late apoptosis. In vivo, immunodeficient SCID mice bearing heterotopic SW620 xenografts were treated daily for 28 days with IQ-1 (30 mg/kg) or TRP-Ox (30, 60, or 90 mg/kg) via intraperitoneal (i.p.) or peritumoral (subcutaneous, s.c.) injection, with oxaliplatin (5 mg/kg, i.p.) as a positive control. Unlike oxaliplatin, IQ-1 showed no antitumor activity by either route. Conversely, TRP-Ox induced xenograft tissue necrosis and dose-dependently reduced post-mortem tumor mass at 30 and 60 mg/kg via both administration routes. However, the 90 mg/kg dose yielded no further reduction, indicating an efficacy plateau likely associated with dose-limiting toxicity. Notably, peritumoral administration significantly outperformed delivery, indicating that the systemic efficacy of TRP-Ox is constrained by low bioavailability. Collectively, these findings identify TRP-Ox as a potent pro-apoptotic lead active against CRC cells and warrant its further preclinical development using advanced drug-delivery formulations.
No takes yet. Share an insight, caveat, or question.
Zavjalov et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: